PLoS ONE (Jan 2015)

Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.

  • Katharina Troppan,
  • Sybille Hofer,
  • Kerstin Wenzl,
  • Markus Lassnig,
  • Beata Pursche,
  • Elisabeth Steinbauer,
  • Marco Wiltgen,
  • Barbara Zulus,
  • Wilfried Renner,
  • Christine Beham-Schmid,
  • Alexander Deutsch,
  • Peter Neumeister

DOI
https://doi.org/10.1371/journal.pone.0123922
Journal volume & issue
Vol. 10, no. 4
p. e0123922

Abstract

Read online

Multiple myeloma (MM) is a malignant clonal expansion of plasma cells in the bone marrow and belongs to the mature B-cell neoplams. The pathogenesis of MM is associated with constitutive NF-κB activation. However, genetic alterations causing constitutive NF-κB activation are still incompletely understood. Since A20 (TNFAIP3) is a suppressor of the NF-κB pathway and is frequently inactivated in various lymphoid malignancies, we investigated the genetic and epigenetic properties of A20 in MM. In total, of 46 patient specimens analyzed, 3 single base pair exchanges, 2 synonymous mutations and one missense mutation were detected by direct sequencing. Gene copy number analysis revealed a reduced A20 gene copy number in 8 of 45 (17.7%) patients. Furthermore, immunohistochemical staining confirmed that A20 expression correlates with the reduction of A20 gene copy number. These data suggest that A20 contributes to tumor formation in a significant fraction of myeloma patients.